Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast03 in residual triple-negative breast cancer after neoadjuvant therapy
2023-505552-22-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Feb 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan and durvalumab in triple-negative breast cancer (TNBC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Invasive disease-free survival. Planned start Feb 2023; status: authorised.
02
Drugs
datopotamab deruxtecandurvalumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-505552-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505552-22-00.